We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I disagree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistic

We use tools such as Google Analytics to track web traffic and check the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Press Releases

Bioxodes raises EUR 2.6 million to develop antithrombotic peptide derived from tick saliva

Bioxodes raises EUR 2.6 million to develop antithrombotic peptide derived from tick saliva
Press Releases
Bioxodes raises EUR 2.6 million to develop antithrombotic peptide derived from tick saliva

Marche-en-Famenne, Belgium, November 2013

Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million first seed funding round with a consortium of business angels and Belgian investment funds. EUR 1.6 million is from the European Regional Development Fund (ERDF) and the Walloon Region in Belgium via the Retech program for Research & Technology.